Utilizing Fed-Batch Intensification To Increase Titer In Biologics Manufacturing

By Ruth Rowland-Jones, Principal Scientist, Global Biologics Technical Development Group, Lonza Biologics

Improving efficiency and productivity in biologics manufacturing is a longstanding goal within today’s industry, especially now as new and increasingly complex molecules are fundamentally changing technological and operational approaches to drug development. Process intensification can help accelerate this pace of innovation through advanced process development techniques and high productivity manufacturing platforms.

Within Lonza’s facilities, the advanced principles of process intensification have been applied to process and equipment design to increase facility throughput, ultimately offering a wide range of benefits to customers. One such approach is through N-1 perfusion, which intensifies the fed-batch process in order to attain high cell density and viability, leading to an increase in product accumulation within the production bioreactor, ultimately leading to a reduction in cost of goods (COGS) at commercial scale.

Download the full article to learn more about Lonza’s intensified fed-batch process as well as a case study highlighting its benefits.